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Abstract
Background: Elevated white blood cell (WBC) count is associated with risk of venous thromboembolism (VTE) in
cancer patients initiating chemotherapy. It is not known whether the risk of VTE by WBC count in cancer patients is
causal or merely a consequence of the malignant disease. To address this question, we studied the association
between WBC count, measured prior to cancer development, and risk of VTE in subjects who did and did not
develop cancer during follow-up in a prospective population-based study.
Methods: Baseline characteristics, including WBC and neutrophil counts, were measured in 24304 initially cancer-
free subjects who participated in the Tromsø Study in 1994-1995. Incident cancer diagnosis and VTE events were
registered up to September 1, 2007. In the cancer cohort, WBC and neutrophil counts were measured in average 7.1
years before cancer development. Cox-regression models were used to calculate hazard ratios (HRs) for VTE by
WBC and neutrophil counts as categorized variables (<40th, 40-80th, and >80th percentile) with 95% confidence
intervals (CIs).
Results: During follow-up, 1720 subjects developed cancer and there were 388 VTE events, of which 116 occurred
in the cancer-group (6.9 per 1000 person-years) and 272 in the cancer-free group (1.1 per 1000 person-years). In
those who developed cancer, WBC count above the 80th percentile (≥8.6x109 cells/L) was associated with a 2.4-fold
higher risk (HR 2.36, 95% CI: 1.44-3.87) of VTE compared to WBC count below the 40th percentile (<6.4x109 cells/L).
No association was found between WBC count and VTE in those who stayed cancer-free (HR 0.94, 95% CI
0.65-1.36). Similar findings were observed for neutrophils.
Comment: Pre-cancer WBC count was associated with risk of VTE in cancer patients, but not in cancer-free
subjects. Our findings suggest that leukocytes may play a causal role in cancer-related VTE rather than only
reflecting the low-grade inflammation associated with cancer.
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Introduction
Venous thromboembolism (VTE), including deep vein
thrombosis (DVT) and pulmonary embolism (PE), is a common
disease with serious short- and long-term consequences. The
overall incidence of VTE is 1-2 per 1000 person-years in
adults, and it increases exponentially with higher age [1–3]. To
date, many acquired and genetic risk factors for VTE have
been identified, and cancer is established as one of the leading
causes of VTE. Overall, cancer is associated with a 5-7 fold
increased risk of VTE [4–6], and approximately 20% of the
incident VTE events are associated with malignancy [1–3].
Cancer patients that develop VTE have shortened life-
expectancy compared to cancer patients without VTE [7,8].
VTE in subjects with cancer also leads to frequent and
prolonged hospitalizations, thereby consuming a substantial
amount of health resources [9]. Furthermore, cancer patients
with VTE more often suffer from recurrent VTE and bleeding
complications during treatment with anticoagulants [10].
Current guidelines do not support thromboprophylaxis to all
cancer patients, stressing the importance of identifying high-
risk groups [11].
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In population-based cohort studies, high leukocyte counts
have been recognized as a risk factor for cancer mortality and
arterial thrombosis [12–15]. Limited knowledge exists,
however, on the association between white blood cell (WBC)
count and risk of VTE. A population-based cohort study of
cancer-free subjects reported no association between WBC
count and risk of VTE [16]. In contrast, leukocytosis was
identified as a risk factor for VTE and mortality in ambulatory
cancer patients [17]. However, it is not known whether the risk
of VTE by WBC count in cancer patients is causal, or merely a
consequence of the malignant disease. The WBC count is
often elevated in subjects with cancer [18], and leukocytes are
shown to be important in cancer progression [19]. Accordingly,
we found it pertinent to investigate whether WBC and
neutrophil counts, the major subtype of WBC, measured prior
to cancer diagnosis were associated with risk of VTE in cancer
and cancer-free subjects recruited from a general population.
Methods
Ethics statement
The study was approved by the Regional Committee for
Medical and Health Research Ethics in Northern Norway (REC
North), and the participants gave their informed written consent
to participate.
Study population
Participants were recruited from the fourth survey of the
Tromsø Study (conducted in 1994-95), a single-center,
population-based cohort study. All inhabitants of the Tromsø
municipality were invited and 77% (n=27 158) of the eligible
population participated. Subjects who were no longer officially
registered as inhabitants of Tromsø at baseline (n= 43), did not
consent to medical research (n=201), had a known VTE prior to
inclusion (n= 48), or missing values for total WBC or neutrophil
count, (n=1679) were excluded from the study population.
Furthermore, subjects with a history of cancer (n=753) or occult
cancer at baseline (i.e. cancer diagnosis <1 year after baseline
inclusion, n=130) were excluded to avoid influence of
preexisting cancer on the WBC measurement. Subjects with
non-melanoma skin cancers (ICD-7 codes: 191.0-191.9) were
regarded as cancer-free subjects, due to the non-metastatic
potential of the disease. Accordingly, the study population
counted 24 304 subjects who were followed for a maximum of
12.9 years. Observational time was calculated for each subject
from the date of enrollment to either the date of VTE, migration,
death or end of follow-up (Sept 1, 2007), whichever came first.
Subjects who got a diagnosis of cancer during follow-up and
subjects who remained cancer-free were analyzed separately.
Baseline measurements
Baseline data was obtained by clinical examination, non-
fasting blood samples and self-administrated questionnaires.
The blood samples were collected from an antecubital vein and
analyses were performed by the Department of Clinical
Chemistry, University Hospital, North Norway. For WBC and
neutrophil counts, 5 ml of blood were collected into Vacutainer
tubes containing EDTA as an anticoagulant (K3- EDTA 40 µL,
0.37 mol/L per tube), and analyzed within 12 hours by an
automated blood cell counter (Coulter Counter®, Coulter
Electronics, Luton, UK). Body weight and height were
measured in subjects wearing light clothing and no shoes.
Body mass index (BMI) was calculated as weight in kilograms,
divided by the square of the height in meters (kg/m2).
Information about physical activity level (average weekly hours
of hard physical activity, i.e. activity causing sweating and/or
breathlessness), current daily smoking (cigarettes/cigar/pipe),
self-reported diabetes and history of cardiovascular disease
[CVD] (angina pectoris, myocardial infarction or stroke) were
obtained from the questionnaires.
Cancer ascertainment
Surveillance of cancer diagnoses in the Norwegian
population is performed by the Cancer Registry of Norway
(CRN) and information about cancer in the cohort was obtained
through linkage to the CRN. The CRN is considered a
complete and valid registry, and in a recent evaluation of data
quality it was found to have a completeness of 98.8% with 94%
of the cases being histologically verified [20]. The CRN
provided information about the date of diagnosis and location
of the disease (ICD-7 codes 140-205).
Venous thromboembolism ascertainment
First life time VTE events were identified by searching the
hospital discharge diagnosis registry, the radiology registry and
the autopsy registry at the University Hospital of North Norway,
as previously described by Brækkan et al [1]. The University
Hospital of North Norway is the only hospital that performs
diagnostic verification and treatment of VTE in the region, and
the discharge diagnosis registry includes both outpatient clinic
visits and hospitalizations. A VTE event was recorded when all
four of the following criteria were fulfilled; (i) objectively
confirmed by diagnostic procedures (compression
ultrasonography, venography, spiral computed tomography,
perfusion-ventilation scanning, pulmonary angiography or
autopsy); (ii) a diagnosis of deep vein thrombosis or pulmonary
embolism made by the physician was written in the medical
record; (iii) signs and symptoms consistent with VTE were
present; and (iv) relevant treatment had been initiated (heparin,
warfarin or similar agent, thrombolytics or vascular surgery).
Registrations made from the autopsy registry required that VTE
was the acknowledged cause of death or a significant
contributor on the death certificate.
Provoking factors other than cancer were systematically
obtained from the medical records of the VTE patients. Such
factors were: recent surgery or trauma within the previous 8
weeks, acute medical conditions (acute MI, ischemic stroke or
major infectious disease), marked immobilization (bed rest for >
3 days, wheelchair use, or long-distance travel exceeding 4
hours within the last 14 days prior to the VTE) or other
provoking factors specifically described by a physician in the
medical record (e.g. intravascular catheter).
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Statistical analyses
Linear regression and chi-square test were used in trend
analyses of continuous and dichotomous baseline variables,
respectively. Crude incidence rates of VTE and cancer were
calculated across WBC categories in both cohorts. Cox
proportional hazards regression models were used to
determine hazard ratios (HR) with 95% confidence intervals.
WBC and neutrophil counts were treated as continuous and
categorized (<40th, 40-80th, and >80th percentiles) variables. In
the categorized analyses, the lower 40th percentile was used as
reference group. In the simple regression model HRs were
adjusted for age and sex, whereas the multivariable model
included age, sex, smoking, BMI, history of CVD, diabetes and
hard physical activity. Multivariable adjusted associations
between WBC count and risk of VTE in cancer and non-cancer
subjects were visualized by generalized additive regression
plots. In these plots, WBC counts (log transformed) were
modeled with a 4-degrees of freedom smoothing spline fit in
Cox proportional hazard models including the same variables
as described above. The proportional hazards assumption was
confirmed by evaluating the parallelism between the curves of
the log-log survivor function. The statistical packages R
(version 2.15.1 for windows) and SPSS (version 19, IBM SPSS
Statistics) were used for the analyses.
Results
In total, 1 720 subjects (7% of the population) were
diagnosed with cancer during follow-up. Table 1 shows
baseline characteristics for the cancer- and non-cancer cohort
over categories of WBC count. In the cancer cohort (n=1 720),
the mean age was higher (58 years) than in the non-cancer
cohort (45 years). Age slightly decreased across increasing
values of total WBC count in both cohorts, as did the proportion
of subjects performing hard physical activity. Daily smoking
was substantially more common across increasing categories
of WBC count in both groups. Minor changes in BMI and no
changes in history of CVD appeared across categories of WBC
count.
Throughout the study period 388 incident VTE events were
registered, and 29% of the VTE events (n = 116) occurred in
the cancer cohort. The clinical characteristics of VTEs
occurring in the cancer- and non-cancer cohort are shown in
table 2. The proportion of VTEs that could be related to one or
more provoking factors other than cancer was similar in both
cohorts (46% and 47%, respectively). Particularly, surgery was
a predisposing event in the same proportion in cancer and non-
cancer subjects. Traumas were more often associated with
VTE in non-cancer patients, whereas other predisposing
factors (i.e. intravascular catheters) more commonly occurred
in cancer patients.
The risk of VTE by WBC and neutrophil counts in cancer and
cancer free subjects are shown in table 3. The mean
observational time was 9.8 years in the cancer cohort and 11.0
years in the non-cancer cohort. The overall crude incidence of
VTE in the cancer cohort was 6.9 per 1000 person-years,
compared to 1.1 per 1000 person-years in the non-cancer
cohort (Table 3). In the cancer cohort, the VTE incidence
increased from 6.2 per 1000 person-years in subjects with
WBC count <6.4 x 109 cells/L to 10.6 per 1000 person-years in
Table 1. Baseline characteristics across categories of total
white blood cell (WBC) count in subjects who developed
cancer and subjects who did not develop cancer during
follow-up.
 Categories of WBC count (109 cells/L) P for trend
 < 6.4 6.4-8.5 ≥ 8.6  
Cancer     
Subjects (n) 671 688 361 -
Age (years) 58.5 ± 13.3 58.2 ± 13.6 55.6 ± 12.8 0.002
Sex (female) 49.0 (329) 51.2 (352) 48.5 (175) 0.9
BMI (kg/m2) 25.9 ± 4.0 25.8 ± 4.2 25.3 ± 3.9 0.06
Daily smoking 21.0 (141) 44.0 (303) 70.6 (255) <0.001
Physical activity (hard) 24.7 (164) 21.3 (145) 16.9 (60) 0.003
Self-reported DM 2.7 (18) 3.8 (26) 3.6 (13) 0.3
Self-reported CVD 11.2 (75) 12.4 (85) 9.4 (34) 0.5
Non-cancer     
Subjects (n) 8884 9214 4486 -
Age (years) 46.1 ± 14.9 45.7 ± 14.6 43.5 ± 13.1 <0.001
Sex (female) 49.7 (4414) 53.0 (4884) 54.7 (2455) <0.001
BMI (kg/m2) 24.9 ± 3.6 25.3 ± 3.9 25.2 ± 4.0 <0.001
Daily smoking 19.0 (1689) 39.3 (3618) 66.0 (2963) <0.001
Physical activity (hard) 35.3 (3121) 30.1 (2753) 27.4 (1218) <0.001
Self-reported DM 1.3 (118) 1.9 (172) 1.4 (64) 0.3
Self-reported CVD 5.3 (475) 6.4 (592) 5.6 (252) 0.2
The Tromsø Study 1994-2007.
Values are given as mean ± 1 standard deviation or as percentages with absolute
numbers in parentheses.
Physical activity (hard) ≥ one hour per week of activity that caused sweating or
breathlessness.
BMI = Body mass index
DM = Diabetes mellitus
CVD = Cardiovascular disease
Table 2. Clinical characteristics of cancer and non-cancer
related venous thromboembolism (VTE) events at the time
of VTE diagnosis.
 Cancer related VTE (n=116) Non-cancer VTE(n=272)
Total provoked* 45.7 (53) 47.4 (129)
Surgery** 15.5 (18) 18.4 (50)
Acute medical condition† 14.7 (17) 16.5 (45)
Trauma** 2.6 (3) 8.5 (23)
Immobilisation‡ 19.0 (22) 17.6 (48)
Other provoking factor§ 6.0 (7) 2.9 (8)
The Tromsø Study 1994-2007.
Values are given as percentages with absolute numbers in parentheses.
*. One or more provoking factors, except for cancer.
**. Within 8 weeks before the VTE event.
†. Myocardial infarction, ischemic stroke or major infectious disease.
‡. Bed rest > 3 days, wheelchair, long haul travel >4 hours in the past 14 days.
§. Other provoking factor described by the physician, e.g. intravascular catheter.
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subjects with total WBC count ≥8.6 x 109 cells/L, whereas the
corresponding rates in the non-cancer cohort were 1.2 and 0.9,
respectively. Figure 1 shows the multivariable adjusted
association of WBC count with VTE in the cancer and non-
cancer cohorts. When analyzed as a continuous variable, the
multivariable-adjusted HR of VTE by one standard deviation
increase (SD =1.96 x 109 cells/L) in WBC count was 1.19 (95%
CI 1.09-1.30) in the cancer cohort and 1.00 (95% CI: 0.87-1.15)
in the non-cancer cohort. In the cancer cohort, WBC count in
the upper category was associated with almost 2-fold
increased risk of VTE (HR 1.95, 95% CI 1.24-3.07), compared
to the lowest category in the simple cox-model adjusted for age
and sex. In the multivariable model, adjusted for age, sex,
smoking, BMI, physical activity, self-reported diabetes mellitus
and cardiovascular disease, the HR was 2.36 (95% CI
1.44-3.87)
Neutrophil count showed similar pattern as total WBC count
in cancer and non-cancer subjects (table 3). The multivariable-
adjusted HR of VTE by one standard deviation increase (SD
=1.54 x 109 cells/L) in neutrophil count was 1.33 (95% CI
1.11-1.61) in the cancer cohort compared to 1.01 (95% CI:
0.88-1.16) in the non-cancer cohort. In the cancer cohort,
subjects with neutrophil count above the 80th percentile (≥5.1 x
109 cells/L) had a non-significant 1.6-fold increased risk (HR
1.56, 95% CI 0.93-2.61) of VTE compared to those with counts
below the 40th percentile (<3.5 x 109 cells/L).
Smoking increases white blood cell count, and is also
associated with cancer and VTE. Therefore, to ensure that the
observed risk of VTE by WBC in cancer patients was not solely
driven by a smoking induced rise in WBC count, we also
conducted analysis restricted to non-smokers. In the cancer
cohort, the multivariate HR for upper versus lower category of
WBC count was 2.23 (95% CI 1.22-4.09), clearly indicating that
the strong association was not confounded by smoking (data
not shown).
The mean time from baseline to cancer diagnosis was 7.1
years. The hazard ratio of cancer did not differ significantly
between the categories of WBC count when the analyses were
adjusted for age, sex, BMI, smoking, physical activity, self-
reported diabetes and CVD (data not shown). Thus, the
observed association of leukocytes and VTE in cancer patients
did not seem to be explained by an increased risk of cancer in
those with a high leukocyte count.
Discussion
This population-based cohort study is, to the best of our
knowledge, the first to identify that pre-cancer leukocyte counts
are associated with future risk of VTE. Cancer patients with
WBC count above the 80th percentile (≥ 8.6 x 109 cells/L),
measured on average 7 years before the cancer diagnosis, had
a 2.4-fold increased risk of VTE compared to those with WBC
count below the 40th percentile (<6.4 x 109 cells/L) in
multivariable analysis. Additionally, we confirmed the original
findings from the LITE study [16] showing that WBC count was
not associated with risk of future VTE in the cancer-free
population.
Table 3. Incidence rates (IRs) and hazard ratios (HRs) for
venous thromboembolism (VTE) by total white blood cell
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*. 109 cells/L
#. Person years
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§. WBC count 1 standard deviation (SD) = 1.98, Neutrophil count 1 SD = 1.54.
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Previous studies have provided growing evidence for a
predictive role of WBC count for risk of VTE in patients with
overt cancer. Ambulatory cancer patients with leukocytosis
(leukocyte count >11 x 109 cells/L) prior to initiation of
chemotherapy had a 2-fold increased risk of VTE [17].
Figure 1.  WBC count and risk of venous
thromboembolism.  Dose–response relationship between
WBC count and risk of VTE in cancer and non-cancer subjects
obtained by generalized linear regression. The regression
models are adjusted for age, sex, BMI, smoking, self-reported
diabetes, physical activity and self-reported CVD. The solid
lines show HRs and the shaded areas show 95% CIs. Density
plots show the distribution of WBC, and white vertical lines
indicate 2.5th, 25th, 50th, 75th and 97.5th percentiles.
doi: 10.1371/journal.pone.0073447.g001
Leukocyte count was also a risk factor for subsequent
thrombosis in cancer patients receiving cisplatin [21] or
gemcitabine [22] chemotherapy. Furthermore, a multicenter,
VTE-registry study found that cancer patients with VTE and
leukocytosis had 1.6-fold increased risk of recurrent VTE,
whereas subjects with low WBC count (<4 x 109 cells/L) had
decreased risk of recurrence, compared to cancer patients with
normal WBC count [23]. However, the design of these studies
made it impossible to discriminate whether the relationship
between WBC count and VTE risk in cancer patients could be
causal or attributed to the presence of other cancer-related
features such as co-morbidities, aggressive malignancy, the
pro-inflammatory milieu or secondary to chemotherapy.
Our findings add to the present knowledge by indicating that
the association between WBC count and risk of VTE observed
in cancer patients is not due to WBC count as an innocent
bystander of the malignant disease. First, leukocyte counts
(total WBC and neutrophil counts) measured at least one year
prior to cancer diagnoses, were associated with future risk of
VTE in cancer patients. Second, the risk estimates for VTE by
leukocyte counts measured prior to cancer development were
similar to the risk estimates in a recent study where leukocyte
counts were measured after cancer diagnoses [17].
Furthermore, in light of the thrombosis potential model [24],
venous thrombosis will occur when a combination of risk
factors reach a certain level (the thrombosis potential).
Accordingly, high WBC count alone did not reach the
thrombosis potential, but in combination with malignancy our
findings support that WBC count contributes to reach the
thrombosis threshold. Thus, the time-sequence of events and
the magnitude of the risk estimates support the concept that
leukocytes may be important in the pathogenesis of venous
thrombosis in the presence of malignancy, but not in the
general cancer-free population.
The mechanisms by which leukocytes contribute to the
pathogenesis of cancer associated VTE is not clear. However,
growing evidence from experimental and clinical studies
indicate that microparticles expressing tissue factor (TF), shed
from cancer cells and activated or apoptotic leukocytes,
especially monocytes, may play an important role in the
pathogenesis of cancer-related venous thrombosis [25–27].
Increased levels of P-selectin, a leukocyte adhesion molecule,
expressed on activated endothelial cells and platelets [28],
have been shown to increase the risk of thrombosis in cancer
patients [29]. Furthermore, interaction between P-selectin and
its ligand on leukocytes (P-selectin glycoprotein-1, PSGL-1)
triggers the release of procoagulant microparticles [30] and
promotes thrombus growth [31,32]. Recent discoveries have
also proposed that neutrophils can be important in thrombus
formation through formation of neutrophil extracellular traps
(NETs) [33]. NETs are webs of DNA released from neutrophils
during high-stress situations like sepsis, and serve as
antibacterial traps [34]. NETs have been demonstrated to
adhere to platelets and red blood cells, as well as to activate
the coagulation cascade, thereby promoting formation of
thrombin [35]. Moreover, a very recent study showed that
neutrophils from mice with cancer were more prone to generate
NETS than those from cancer free mice, suggesting that
WBC Count and Venous Thromboembolism
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cancers predispose neutrophils to release extracellular DNA
traps that contribute to cancer-associated thrombosis [36].
Previous population-based cohort studies have shown that
leukocyte count in itself is predictive of cancer development
and cancer associated mortality [15,37]. Thus, an elevated
leukocyte count could represent a common underlying risk
factor for cancer and VTE. In our study, however, leukocyte
count was not a risk factor for cancer development. A possible
explanation could be that those with a high leukocyte count at
baseline developed a more aggressive type of cancer with a
higher thrombotic potential. Unfortunately, due to lack of
statistical power, we were not able to do sub-group analyses
on risk of VTE by various cancer sites.
The main strengths of our study are the prospective design,
the large population recruited from a general population, the
long term follow-up, and validated exposure and endpoints.
The VTE events were systematically validated and objectively
confirmed, and as the University Hospital of North Norway is
the only diagnostic and treating institution for VTE in the region,
it is likely that the majority of the VTE events in the population
were recorded. Likewise, the Cancer Registry of Norway has
high completeness and validity. The Tromsø Study consists of
repeated surveys (1994-95, 2001-02, 2007-08), and a
subgroup of the participants was invited to participate in all the
six surveys. This allows for an evaluation of variation in certain
exposure variables over time. Some limitations of the study
should also be mentioned. First, only one measurement of
WBC count was available for the whole study population, and
the risk estimates were based solely on this measurement.
However in our sub-population of subjects who attended
several surveys, 69% of the subjects who were initially
(1994-95) categorized in the upper range of WBC count, were
categorized similarly at the next measurement (2001-02). In
general, intra-individual variation in an exposure variable
weakens the statistical associations, and this is especially
important during long-term follow-up (regression dilution effect).
Furthermore, information about cancer treatment was not
available in our study, and the size of the cancer cohort
restricted the possibilities of sub-group analyses (e.g. cancer
sites and stages).
In conclusion, leukocyte count was a risk factor for venous
thrombosis in subjects who developed cancer during follow-up,
but not in the cancer-free population. Our findings suggest that
leukocytes may play a role in the pathogenesis of venous
thrombosis in the presence of a malignant environment.
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